Quarterly report pursuant to Section 13 or 15(d)

Revenue (Details)

v3.10.0.1
Revenue (Details)
 3 Months Ended 6 Months Ended
Jun. 30, 2018
USD ($)
customer
Jun. 30, 2017
USD ($)
Jun. 30, 2018
USD ($)
item
customer
Jun. 30, 2017
USD ($)
Jan. 01, 2018
USD ($)
Dec. 31, 2017
USD ($)
Disaggregation of revenue            
Revenue $ 9,038,000 $ 3,521,000 $ 17,234,000 $ 6,378,000    
Change in Contract with Customer, Liability [Abstract]            
Deferred revenue at beginning of the period     30,090,000      
Cumulative effect of adopting ASC 606           $ 8,645,000
Revenue recognized included in contract liability at beginning of the period     11,910,000      
Change in variable consideration     (10,396,000)      
Change in percentage of completion     5,072,000      
Revenue (9,038,000) $ (3,521,000) (17,234,000) $ (6,378,000)    
Amounts invoiced in the period     4,210,000      
Foreign exchange translation adjustment     (344,000)      
Deferred revenue at end of the period 16,722,000   16,722,000      
Contract assets, liability and receivables            
Remaining performance obligation 42,653,000   42,653,000      
ASU 2014-09            
Change in Contract with Customer, Liability [Abstract]            
Cumulative effect of adopting ASC 606         $ (8,645,000)  
NY-ESO program            
Contract assets, liability and receivables            
Remaining performance obligation 946,000   946,000      
NY-ESO SPEAR T-cell therapy program            
Contract assets, liability and receivables            
Remaining performance obligation 39,593,000   39,593,000      
PRAME program            
Contract assets, liability and receivables            
Remaining performance obligation 2,114,000   2,114,000      
Under previous revenue guidance            
Change in Contract with Customer, Liability [Abstract]            
Deferred revenue at beginning of the period     38,735,000      
Under previous revenue guidance | ASU 2014-09            
Disaggregation of revenue            
Revenue 3,267,000   12,263,000      
Change in Contract with Customer, Liability [Abstract]            
Revenue (3,267,000)   (12,263,000)      
Development            
Disaggregation of revenue            
Revenue 9,038,000   17,234,000      
Change in Contract with Customer, Liability [Abstract]            
Revenue $ (9,038,000)   $ (17,234,000)      
GlaxoSmithKline Intellectual Property Development Ltd            
Contract assets, liability and receivables            
Number of customers | customer 1   1      
Number of geographic locations | item     1